Only two medications have full FDA approval for treating PTSD: sertraline (Zoloft) and paroxetine (Paxil), both selective serotonin reuptake inhibitors. Across large trials, these drugs improve symptoms in roughly six out of ten people who take them, compared to about a third who improve on placebo. That gap is real but modest, and it leaves a substantial number of people searching for alternatives, which is why the medication landscape for PTSD extends well beyond those two pills into off-label prescribing, symptom-targeted drugs, and a wave of experimental agents that work in fundamentally different ways.
The Two FDA-Approved Options and How Well They Actually Work
A Cochrane review pooling eight trials with over a thousand participants found that SSRIs improved PTSD symptoms in about 58% of participants, versus 35% on placebo.1PubMed Central. Pharmacotherapy for post traumatic stress disorder (PTSD) That translates to roughly one extra person benefiting for every four or five treated. A separate meta-analysis calculated that you need to treat about seven to ten patients for around eleven weeks of medication before one additional person responds compared to what placebo would have done.2International Journal of Neuropsychopharmacology. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD) These are honest, middling numbers, and they help explain why clinicians so often reach beyond the approved options.
Between the two approved drugs, paroxetine has shown larger symptom reductions in head-to-head comparisons. That same meta-analysis found paroxetine significantly outperformed sertraline and fluoxetine in reducing overall symptom severity.3International Journal of Neuropsychopharmacology. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD) Yet paroxetine comes with notable trade-offs: it is one of the antidepressants most associated with withdrawal symptoms when stopped, including dizziness, mood swings, and sleep problems. Sertraline tends to be better tolerated during discontinuation, which is one reason many clinicians start there. Another meta-analysis found that while sertraline outperformed other medications overall, paroxetine and fluoxetine showed only small improvements, and several other drugs, including citalopram, mirtazapine, and divalproex, failed to separate from placebo at all.4PubMed. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: Systemic review and meta-analyses to determine first-line treatments
Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, is sometimes treated as a quasi-first-line choice. It showed large initial effects in that same analysis, though those effects faded over time.5PubMed. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: Systemic review and meta-analyses to determine first-line treatments Venlafaxine also carries a higher withdrawal risk, making it a drug that works well for some people but demands careful planning around stopping.
Prazosin for Nightmares and Sleep Disturbance
PTSD nightmares are a specific, often devastating symptom that first-line antidepressants do not reliably fix. This is where prazosin has carved out a distinct role. Originally a blood-pressure drug, prazosin blocks a type of adrenaline receptor in the brain, which dials down the norepinephrine activity thought to drive trauma-related nightmares.6PubMed Central. Prazosin for the treatment of nightmares related to posttraumatic stress disorder: a review of the literature
Five out of seven randomized controlled trials concluded that prazosin effectively reduces nightmares and improves both sleep quality and total sleep time.7PubMed Central. Using Prazosin to Treat Posttraumatic Stress Disorder and Associations: A Systematic Review A more recent review confirmed that prazosin still has the best evidence base of any drug for PTSD-related nightmares, though it acknowledged that the drug works better in some subgroups than others.8PubMed. Effects of Prazosin and Other Alpha-1 Adrenergic Antagonist Drugs on Nightmares and Sleep Disturbances in Posttraumatic Stress Disorder The practical caveat is that prazosin lowers blood pressure, so it requires dose titration and monitoring, especially at the start. First-dose dizziness is the most common complaint.
Prazosin’s story took a confusing turn in 2018 when a large VA-funded trial (the RASKIND study, not in the source list here) failed to show benefit over placebo for active-duty military and veterans. That result was surprising and controversial. Subsequent analyses have suggested the discrepancy may relate to the study population and methodology rather than the drug itself, and the weight of the overall evidence still favors prazosin for nightmare-predominant PTSD.
Atypical Antipsychotics as Add-On Treatment
When SSRIs alone are not enough, clinicians sometimes add a low-dose atypical antipsychotic. This is entirely off-label for PTSD, but it has meaningful evidence behind it. A meta-analysis of randomized trials found that atypical antipsychotics reduced overall PTSD severity scores compared to placebo, with particularly strong effects on intrusive memories and hyperarousal symptoms.9PubMed. Efficacy and acceptability of atypical antipsychotics for the treatment of post-traumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials Dropout rates were no different from placebo, which suggests people tolerate them reasonably well in the short term.
Olanzapine has some of the clearest data. A double-blind trial in veterans with combat-related PTSD who had not responded to SSRIs alone found that adding olanzapine significantly reduced PTSD, depressive, and sleep symptoms.10PubMed. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study A broader review found that atypical antipsychotics were effective and generally safe for PTSD, and also helped with the anxiety, depression, and occasionally psychotic features that often accompany it.11Clinical Neuropharmacology. Atypical Antipsychotics in the Treatment of Posttraumatic Stress Disorder The catch is metabolic side effects: weight gain, blood sugar changes, and cholesterol shifts are real concerns with longer use, especially for olanzapine and quetiapine.
Topiramate and Other Anticonvulsants
Topiramate, an anticonvulsant sometimes used for migraines, has attracted interest for PTSD because of its effects on brain excitability. The evidence, though, is genuinely mixed. One trial reported large effect sizes for overall symptom reduction, a second found benefit only for re-experiencing symptoms, and a third showed no significant advantage over placebo.12PubMed Central. Topiramate as a therapy for chronic posttraumatic stress disorder A meta-analysis found only a small, statistically significant reduction in hyperarousal, with no significant improvement in overall PTSD scores or re-experiencing.13JOURNAL OF TRAUMATIC STRESS. Topiramate as Monotherapy or Adjunctive Treatment for Posttraumatic Stress Disorder: A Meta-Analysis
A randomized controlled trial specifically testing topiramate as add-on therapy for combat-related PTSD found no significant effect on primary outcomes, though the high dropout rate in the treatment group made it hard to draw firm conclusions.14Journal of Clinical Psychopharmacology. A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation Topiramate for Chronic Combat-Related Posttraumatic Stress Disorder Topiramate can cause cognitive side effects, sometimes called “dopamax” informally because of the brain fog some people experience. Given the weak evidence and the side-effect profile, it remains a last-resort option.
Propranolol and the Idea of Memory Disruption
Propranolol works on a different principle from most PTSD drugs. Instead of managing symptoms day to day, it targets the fear memory itself. The theory is that every time you recall a traumatic memory, it briefly becomes malleable before your brain “re-saves” it. If you block adrenaline signaling with propranolol during that window, the emotional charge of the memory may weaken. A randomized controlled trial found that giving propranolol before a guided recall of the trauma reduced PTSD symptoms, with the researchers calling it a “novel and efficacious treatment.”15PubMed. Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial
Timing matters. Propranolol appears most effective when given soon after trauma, when psychological stress is high, and possibly less effective for people who have lived with PTSD for years, where the fear memories have become more deeply consolidated.16PubMed Central. Revisiting propranolol and PTSD: Memory erasure or extinction enhancement? This is not a drug you take daily for ongoing symptoms; it is a targeted intervention used alongside a specific behavioral protocol. That makes it hard to study in conventional ways and limits its practical availability, but the underlying idea, weakening a traumatic memory’s emotional grip, has generated a lot of interest.
Medications vs. Therapy, and Why the Comparison Changes Over Time
A large network meta-analysis compared medications, psychotherapy, and their combination across all available trials. At the end of active treatment, no approach was clearly superior to another: drugs, therapy, and the combination performed similarly.17JAMA Psychiatry. Comparative Efficacy and Acceptability of Pharmacological, Psychotherapeutic, and Combination Treatments in Adults With Posttraumatic Stress Disorder The picture changed at longer follow-up, however. Psychotherapy maintained its benefits better than medication alone, and the combination of both was significantly more beneficial than medication by itself.18JAMA Psychiatry. Comparative Efficacy and Acceptability of Pharmacological, Psychotherapeutic, and Combination Treatments in Adults With Posttraumatic Stress Disorder
The practical takeaway is that medication is not a lesser choice, but it is often a bridge. It can bring symptoms down enough for you to engage in trauma-focused therapy, and the therapy is what tends to produce the most durable change. If therapy is not accessible or tolerable at the start, medication alone is still worth pursuing. But the data suggest planning an eventual path to therapy when possible.
Why SSRIs Do Not Work the Same Way for Children
This is a point that surprises many people: the medications that work in adult PTSD often fail in children. A double-blind trial of sertraline in children and adolescents with PTSD found no difference from placebo after ten weeks of treatment. Both groups improved, but the drug did not add anything beyond what the placebo effect provided. Attrition was also higher in the sertraline group, and about 7.5% of those on sertraline stopped because of side effects.19PubMed. Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial
Prazosin, on the other hand, has shown more encouraging results in younger populations. A case series of 18 pediatric patients found that prazosin at modest doses improved overall PTSD scores by about two-thirds within a month, with no adverse effects aside from one case of low blood pressure.20PubMed Central. Use of Prazosin for Pediatric Post-Traumatic Stress Disorder With Nightmares and/or Sleep Disorder: Case Series of 18 Patients Prospectively Assessed That is a small, uncontrolled study, so the results should be interpreted cautiously. But the broader pattern is clear: first-line adult PTSD drugs should not be assumed to work in children, and trauma-focused psychotherapy remains the primary treatment recommendation for pediatric PTSD in most guidelines.
MDMA-Assisted Therapy
MDMA (the active compound in ecstasy) paired with structured psychotherapy has generated some of the most dramatic results in PTSD treatment research. In a phase 3 trial, participants with severe PTSD who received MDMA-assisted therapy saw their symptom scores drop by an average of about 24 points, compared to roughly 14 points in the placebo-plus-therapy group, a large effect size.21PubMed Central. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study There were no signs of abuse potential, suicidality, or heart-rhythm problems. MDMA appears to work by boosting serotonin, dopamine, norepinephrine, and oxytocin simultaneously, which reduces fear and defensiveness enough for people to process traumatic memories during therapy without becoming overwhelmed.22PubMed Central. MDMA-Based Psychotherapy in Treatment-Resistant Post-Traumatic Stress Disorder (PTSD): A Brief Narrative Overview of Current Evidence
Despite these results, the FDA declined to approve MDMA-assisted therapy in 2024, citing concerns about trial methodology and potential risks. That decision was controversial, and new trials are either underway or being planned. For now, MDMA-assisted therapy is not legally available outside research settings in the United States, though it has been identified as one of the most promising options for treatment-resistant PTSD alongside ketamine and transcranial magnetic stimulation.23PubMed Central. Predicting and Managing Treatment Non-Response in Posttraumatic Stress Disorder
Ketamine and Psilocybin
Ketamine, already used clinically for treatment-resistant depression, is being explored for PTSD through a different lens. It works on glutamate signaling rather than serotonin, and appears to rapidly increase the number and function of connections between nerve cells in the prefrontal cortex, reversing some of the brain changes caused by chronic stress.24JAMA Psychiatry. Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder: A Randomized Clinical Trial These changes in brain plasticity may explain why some patients report rapid improvement in PTSD symptoms after even a single infusion, though the effects tend to fade within days to weeks without repeated sessions.25PubMed Central. Molecular pathways of ketamine: A systematic review of immediate and sustained effects on PTSD
Psilocybin, the active compound in psychedelic mushrooms, is at an earlier stage. An open-label study in traumatized AIDS survivors found that psilocybin-assisted therapy reduced PTSD symptoms, attachment anxiety, and demoralization.26PubMed. Psilocybin for Trauma-Related Disorders Early evidence suggests it may help people confront traumatic memories while reducing emotional avoidance and increasing self-compassion. But these are preliminary findings from small, uncontrolled studies. Psilocybin for PTSD is years behind MDMA in the clinical development pipeline.
Hydrocortisone as Prevention After Trauma
One of the more counterintuitive findings in PTSD pharmacology involves hydrocortisone, a synthetic version of the stress hormone cortisol. You might expect that adding stress hormones after trauma would make things worse. But a meta-analysis found the opposite: hydrocortisone given shortly after trauma significantly reduced both the severity of subsequent PTSD symptoms and the likelihood of developing the disorder at all.27PubMed. Hydrocortisone administration for reducing post-traumatic stress symptoms: A systematic review and meta-analysis The effect was large in preventive use, with people who received hydrocortisone near the time of trauma reporting substantially fewer symptoms at one- and three-month follow-ups than those who received placebo.28PubMed Central. The efficacy of initial hydrocortisone administration at preventing posttraumatic distress in adult trauma patients: a randomized trial
The key qualifier: hydrocortisone did not help when given as a treatment for established PTSD.29PubMed. Hydrocortisone administration for reducing post-traumatic stress symptoms: A systematic review and meta-analysis Its benefit appears to be limited to the narrow window after trauma and before the disorder consolidates. This makes it impractical for most civilian trauma situations, where you would need someone to receive the drug in an emergency room shortly after an event. But for predictable high-trauma settings like surgery or combat deployment, there is growing interest in whether a brief course of hydrocortisone could be protective.
The Endocannabinoid System and Other Experimental Targets
Researchers have been investigating whether boosting the body’s own endocannabinoid system could help with PTSD. Anandamide, an endocannabinoid the brain naturally produces, plays a role in fear extinction, the process by which you learn that a previously threatening cue is now safe. In rats, blocking the enzyme that breaks down anandamide (called FAAH) normalized startle responses and restored healthy fear extinction after a traumatic stressor.30PubMed. Chronic treatment with URB597 ameliorates post-stress symptoms in a rat model of PTSD In healthy humans, FAAH inhibition produced a tenfold increase in anandamide and strengthened recall of fear extinction memories.31PubMed. Elevated Anandamide, Enhanced Recall of Fear Extinction, and Attenuated Stress Responses Following Inhibition of Fatty Acid Amide Hydrolase: A Randomized, Controlled Experimental Medicine Trial
That story looked very promising until it hit the clinic. A randomized trial combining a FAAH inhibitor with internet-delivered cognitive behavioral therapy found that the drug increased anandamide levels as expected but did not improve PTSD symptoms any more than therapy plus placebo.32Neuropsychopharmacology. The efficacy of elevating anandamide via inhibition of fatty acid amide hydrolase (FAAH) combined with internet-delivered cognitive behavioral therapy in the treatment of post-traumatic stress disorder: a randomized, placebo-controlled clinical trial This is a common pattern in PTSD drug development: the biology makes sense, the animal data look strong, and then the human trial disappoints. It does not mean the endocannabinoid approach is dead, but it does mean the path from mechanism to medicine is far from straightforward.
Neuropeptide Y (NPY) is another molecule under investigation. Studies in combat veterans have found direct associations between NPY levels in spinal fluid and PTSD diagnosis, and animal research supports a role for NPY in stress responses, anxiety, and fear regulation.33PubMed Central. Neuropeptide Y (NPY) and posttraumatic stress disorder (PTSD): A translational update No NPY-based drug is in clinical trials for PTSD yet, but it represents one of the more biologically grounded targets under exploration.
BDNF and Why Some Treatments Stick Better Than Others
One protein that keeps showing up across PTSD research is brain-derived neurotrophic factor, or BDNF. It supports the growth and strengthening of connections between nerve cells, and it is essential for fear extinction learning. When BDNF signaling is robust, the brain can more easily form new associations that override old fear memories. Antidepressants, ketamine, and even behavioral therapies all appear to work partly through this system.34PubMed Central. Fear extinction and BDNF: translating animal models of PTSD to the clinic
A study of veterans completing an intensive PTSD treatment program found that higher BDNF levels after treatment predicted significantly lower PTSD symptoms three months later, as well as greater overall improvement from baseline.35PubMed Central. Brain Derived Neurotrophic Factor and Treatment Outcomes Among Veterans Attending an Intensive Treatment Program for Posttraumatic Stress Disorder That finding is preliminary, based on a small group, but it raises an intriguing possibility: BDNF levels might eventually serve as a biomarker to predict which patients will hold onto their treatment gains and which might relapse. It also suggests that any intervention that boosts brain plasticity, whether pharmacological or behavioral, may help PTSD treatment effects last longer.
Stopping Medication and What to Expect
Discontinuation is a practical concern that gets too little attention. Withdrawal symptoms from antidepressants typically include dizziness, headache, sleep disruption, and mood swings. These are usually mild and self-limiting, but the risk varies considerably by drug. Paroxetine and venlafaxine carry the highest withdrawal risk among commonly used PTSD medications, while fluoxetine, with its long half-life, rarely causes problems even with abrupt discontinuation. Gradual tapering over weeks is standard practice for most SSRIs and SNRIs, and your prescriber should have a plan for this before you start.
There is also some evidence of rebound phenomena, meaning that stopping an antidepressant can trigger a relapse that is worse than the original episode. This is different from simple withdrawal and reflects a genuine return of the underlying condition, possibly exacerbated by the neurochemical adjustment of coming off medication. The practical lesson is that discontinuation should be deliberate and monitored, ideally timed to coincide with a period of stability and, if possible, engagement in ongoing therapy.
Sex Differences in Medication Response
PTSD affects women at roughly twice the rate of men, but most large drug trials have been conducted predominantly in male veterans. This creates real gaps in what we know. A recent epidemiological study found possible sex differences in how antihypertensive medications, including drugs in the same class as prazosin, relate to PTSD incidence, though the results were imprecise enough to require cautious interpretation.36PubMed Central. Sex Differences in Antihypertensive Medications and PTSD Incidence The broader problem is not that any drug has been shown to work differently in women versus men, but that the question has rarely been studied well enough to answer. Neuroimaging research has shown that SSRIs increase activity in brain regions involved in emotion regulation in PTSD patients, but these studies too are often small and male-dominated.37PubMed Central. Emotion Regulatory Brain Function and SSRI Treatment in PTSD: Neural Correlates and Predictors of Change Until trials are designed to detect sex-based differences, women with PTSD are largely being treated based on evidence from male samples.